RE:ASCO 2024-Pharma steers clear from radiolignd & cell therapy Clearly all of that dialog bodes well for ONC, Pelareorep.
on wait & see mode.
While that article refers to Merck, no doubt Roche would be along the same line of thought.
Back, not too many years ago: The treatment regimen was Radiation to shrink tumours, various chemo & a plethora of pain meds.
Now, much of the old, standard of care still is inplace.
The additions of imuotherspies. oNCs Pelareorep for example, lights up the cold ( hidden) cancer cells & allows the imune system to function better.
As well as expanded markets for the very effective drugs like tecentriq.
however only 20% of population responds to that treatment.
intrroducing Pela, will expand that treatment option.
The muti billion $$ question, by how much.
imagine the comericial opportunity if they could double the patient base?
One if the many opportunities being investigated.
many of the recent poster/ abstract presentations show that improvement.
next step, a buyout or partnership to move forward with phase 3 & eventual FDA approval.
As mentioned in the article cancers do not have a one size fits all treatment.
those looking for a quick trade. Onc is not the best place to be.
Want to be part of a possible, Canadian cancer blockbuster theraoy, oncolytics biotech is very close.
im in for the big payoff. That is why I say SP does not matter.
should they get bought out, license or final approval, the SP will be many multiples of the silly low numbers we see now.
As displayed by noteable, many buyouts have been multi billions for companies offering a lot less than Onc,s present situation.
sure it's nice to see the sp go up. Reality ...for me. I'm not selling until a business development is announced.
so, I don't care.
When Onc gets to the parnership and/ or buyout. Then the " shareholder value" Will be realized.
Not before.
great day all.
stay healthy & safe.